TDD

Biodegradable Polymers Properties and Applications

[{“box”:0,”content”:”

n

n

 > 

n

n

 > 

n

n

n

n

n

n

n

By [foreach 286]u00a0

u00a0Amit Chawla, Payal Chawla, Arsh Chanana, Vikramjit Singh,

[/foreach]
nJanuary 10, 2023 at 6:28 am

n

nAbstract

n

Polymers that can degrade into biologically compatible components under physiologic conditions present a far more attractive alternative for the preparation of drug delivery systems. The use of biodegradable polymers precludes the need for retrieval at the conclusion of the dosing regimen, thereby avoiding the potential complications associated with the use of non-degradable systems. A wide variety of approaches are continuously being pursued in the quest for improved biodegradable drug delivery systems. New and modified polymer chemistries that offer distinctive degradation and drug delivery attributes are being identified and evaluated. At the same time, innovative engineering and manufacturing methods are under development to fabricate devices and physical platforms having novel three-dimensional structural attributes. In certain instances, these products make it possible to treat entirely new therapeutic applications using biodegradable devices.

n

n

n

n

Volume :u00a0u00a08 | Issue :u00a0u00a02 | Received :u00a0u00a0July 8, 2021 | Accepted :u00a0u00a0August 10, 2021 | Published :u00a0u00a0August 25, 2021n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)] [/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue Biodegradable Polymers Properties and Applications under section in Trends in Drug Delivery(tdd)] [/if 424]
Keywords Biodegradable, polymers, drug delivery, biodegradation, physiologic

n

n

n

n

n


n[if 992 equals=”Transformative”]

n

n

Full Text

n

n

n

[/if 992][if 992 not_equal=”Transformative”]

n

n

Full Text

n

n

n

[/if 992] n


nn

[if 379 not_equal=””]n

[foreach 379]n

n[/foreach]

n[/if 379]

n

References

n[if 1104 equals=””]n

1. Swarbrick James. Encyclopedia of Pharmaceutical Technology. 3rd Edn. Vol. 1. Pinehurst, North Carolinia, USA: PharmaceuTech, Inc.; 2007; 176–190.
2. Chandra, Rustgi. Biodegradable polymers. Prog Polym Sci. Vol. 23. Great Britain: Elsevier Science Ltd.; 1998; 1273–1335.
3. Mitrus, et al. Biodegradable Polymers and Their Practical Utility. In Janssen Leon PBM, Leszek Moscicki, editors. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2009; 1–34.
4. Vroman, Tighzert. Biodegradable Polymers. Materials. 2009; 2(2): 307–344. Online at https://www.mdpi.com/1996-1944/2/2/307 [Access on 05-09-12].
5. Park, et al. Biodegradable Polymers for Microencapsulation of Drugs. Molecules. 2005; 10(1): 146–61.
6. Ikada and Tsuji. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun. 2000; 21(3): 117–125.
7. Razak, et al. Biodegradable Polymers and their Bone Applications: A Review. Int J Basic Appl Sci. 2012; 12(01): 31–44.
8. Aggarwal, et al. Drug delivery: special emphasis given on biodegradable polymers. Advances in Polymer Science and Technology: An International Journal; Universal Research Publications. 2011; 2(1): 1–15.
9. Middleton, et al. Synthetic biodegradable polymers as orthopedic devices. Elsevier Science Ltd., Biomaterials. 2000; 21(23): 2335–2346.
10. Winzenburg, et al. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems. Adv Drug Deliv Rev, Elsevier. 2004; 56(10): 1453–66.
11. Guzman, et al. Biodegradable polymers for food packaging – factors influencing their degradation and certification types –a comprehensive review. Chem Chem Technol. 2011; 5(1): 115–118.
12. Wikipedia. Biodegradable Polymers. Online Available at < [Accessed on 30-05-21].

nn[/if 1104] [if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””], [/if 1106]
  2. n[/foreach]

n[/if 1104]

n[if 1114 equals=”Yes”]n

n[/if 1114]

n

n

[if 424 not_equal=”Regular Issue”] Regular Issue[/if 424] Open Access Article

n

Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

n

“},{“box”:4,”content”:”

n“},{“box”:1,”content”:”

    By  [foreach 286]n

  1. n

    Amit Chawla, Payal Chawla, Arsh Chanana, Vikramjit Singh

    n

  2. [/foreach]

n

    [foreach 286] [if 1175 not_equal=””]n t

  1. Principal, Head Professor, Assistant Professor, Student,Department of Pharmaceutical Sciences, Maa Saraswati Institute of Pharmaceutical Sciences, Abohar, Department of Pharmaceutical Sciences, Maa Saraswati Institute of Pharmaceutical Sciences, Abohar, Department of Pharmaceutical Sciences, Maa Saraswati Institute of Pharmaceutical Sciences, Abohar, Department of Pharmaceutical Sciences, Maa Saraswati Institute of Pharmaceutical Sciences, Abohar,Punjab, Punjab, Punjab, Punjab,India, India, India, India
  2. n[/if 1175][/foreach]

n

n

n

n

n

Abstract

nPolymers that can degrade into biologically compatible components under physiologic conditions present a far more attractive alternative for the preparation of drug delivery systems. The use of biodegradable polymers precludes the need for retrieval at the conclusion of the dosing regimen, thereby avoiding the potential complications associated with the use of non-degradable systems. A wide variety of approaches are continuously being pursued in the quest for improved biodegradable drug delivery systems. New and modified polymer chemistries that offer distinctive degradation and drug delivery attributes are being identified and evaluated. At the same time, innovative engineering and manufacturing methods are under development to fabricate devices and physical platforms having novel three-dimensional structural attributes. In certain instances, these products make it possible to treat entirely new therapeutic applications using biodegradable devices.n

n

n

Keywords: Biodegradable, polymers, drug delivery, biodegradation, physiologic

n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)]

n[/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue under section in Trends in Drug Delivery(tdd)] [/if 424]

n

n

n


n[if 992 equals=”Transformative”]n

n

n

Full Text

n

n

nn[/if 992]n[if 992 not_equal=”Transformative”]n

n

Full Text

n

n

n

n


[/if 992]n[if 379 not_equal=””]

Browse Figures

n

n

[foreach 379]n

n[/foreach]

n

[/if 379]n

n

References

n[if 1104 equals=””]

1. Swarbrick James. Encyclopedia of Pharmaceutical Technology. 3rd Edn. Vol. 1. Pinehurst, North Carolinia, USA: PharmaceuTech, Inc.; 2007; 176–190.
2. Chandra, Rustgi. Biodegradable polymers. Prog Polym Sci. Vol. 23. Great Britain: Elsevier Science Ltd.; 1998; 1273–1335.
3. Mitrus, et al. Biodegradable Polymers and Their Practical Utility. In Janssen Leon PBM, Leszek Moscicki, editors. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2009; 1–34.
4. Vroman, Tighzert. Biodegradable Polymers. Materials. 2009; 2(2): 307–344. Online at https://www.mdpi.com/1996-1944/2/2/307 [Access on 05-09-12].
5. Park, et al. Biodegradable Polymers for Microencapsulation of Drugs. Molecules. 2005; 10(1): 146–61.
6. Ikada and Tsuji. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun. 2000; 21(3): 117–125.
7. Razak, et al. Biodegradable Polymers and their Bone Applications: A Review. Int J Basic Appl Sci. 2012; 12(01): 31–44.
8. Aggarwal, et al. Drug delivery: special emphasis given on biodegradable polymers. Advances in Polymer Science and Technology: An International Journal; Universal Research Publications. 2011; 2(1): 1–15.
9. Middleton, et al. Synthetic biodegradable polymers as orthopedic devices. Elsevier Science Ltd., Biomaterials. 2000; 21(23): 2335–2346.
10. Winzenburg, et al. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems. Adv Drug Deliv Rev, Elsevier. 2004; 56(10): 1453–66.
11. Guzman, et al. Biodegradable polymers for food packaging – factors influencing their degradation and certification types –a comprehensive review. Chem Chem Technol. 2011; 5(1): 115–118.
12. Wikipedia. Biodegradable Polymers. Online Available at < [Accessed on 30-05-21].

n[/if 1104][if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
  2. n[/foreach]

n[/if 1104]

n


n[if 1114 equals=”Yes”]n

n[/if 1114]”},{“box”:2,”content”:”

Regular Issue Open Access Article

n

n

n

n

n

Trends in Drug Delivery

n

[if 344 not_equal=””]ISSN: 2394-7268[/if 344]

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

Volume 8
Issue 2
Received July 8, 2021
Accepted August 10, 2021
Published August 25, 2021

n

n

n

n

Editor

n

n


n

Reviewer

n

n


n n

n”},{“box”:6,”content”:”“}]

Read More
TDD

Recent Advances in Delivering Strategies of Domperidone Challenges and Opportunities

[{“box”:0,”content”:”

n

n

 > 

n

n

 > 

n

n

n

n

n

n

n

By [foreach 286]u00a0

u00a0M.A.K. Azad, Md. Masudur Rahman, Shimul Halder, Eva Rahman Kabir,

[/foreach]
nJanuary 10, 2023 at 6:57 am

n

nAbstract

n

Domperidone (DMP), a potent gastroprokinetic and antiemetic drug, exhibits poor aqueous solubility and limited oral bioavailability. Therefore, to develop oral preparations with optimized oral bioavailability, the pharmacokinetic parameters of DMP need to be controlled. The present review aimed to discuss the physicochemical characteristics of DMP causing its unfavorable oral delivery, to explore the viable oral formulation approaches, and to propose some recent formulation approaches that can mitigate the above mentioned difficulties in delivering DMP. In this study, some effective strategies in terms of pharmacokinetic behavior of DMP have been comparatively discussed. It has been recommended that, the amorphous solid dispersion approach could be more convincing from the scalability perspective along with its significant improvement in dissolution behavior and oral bioavailability. Finally, some future perspectives of these strategies have also been addressed to facilitate efficient formulation development.

n

n

n

n

Volume :u00a0u00a08 | Issue :u00a0u00a02 | Received :u00a0u00a0May 27, 2021 | Accepted :u00a0u00a0August 10, 2021 | Published :u00a0u00a0August 25, 2021n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)] [/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue Recent Advances in Delivering Strategies of Domperidone Challenges and Opportunities under section in Trends in Drug Delivery(tdd)] [/if 424]
Keywords Domperidone; solubility; drug delivery strategy; pharmacokinetic, bioavailability.

n

n

n

n

n


n[if 992 equals=”Transformative”]

n

n

Full Text

n

n

n

[/if 992][if 992 not_equal=”Transformative”]

n

n

Full Text

n

n

n

[/if 992] n


nn

[if 379 not_equal=””]n

[foreach 379]n

n[/foreach]

n[/if 379]

n

References

n[if 1104 equals=””]n

1. Vetrivel N, Praveen D, Ranadheer Chowdary P, Elan Cheziyan K, Vijey Aanandhi M. Comparison of safety and effectiveness of ondansetron and domperidone in patients with gastrointestinal problems. Drug Invent Today. 2018;10(3):343–6.
2. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6(6):571–6.
3. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005;81(1):211–9.
4. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: A Review of its Pharmacological Activity, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic. Drugs. 1982;24(5):360–400.
5. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: Review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm Res An Off J Am Assoc Pharm Sci. 1995;12(3):413–20.
7. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144–56.
8. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm. 2011;420(1):1–10.
9. Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P, et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137.
10. Patel K, Prasad RK, Bajpai M. Enhancement of dissolution rate of domperidone using melt granulation technique. Der Pharm Lett. 2011;3(2):25–33.
11. Tyagi R, Dhillon V. Enhancement of Solubility and Dissolution Rate of Domperidone Using Cogrinding and Kneading Technique. J Drug Deliv Ther. 2012 Jul 15;2(4):152–4.
12. Stephen Olaribigbe Majekodunmi, Cynthia Chibuzor Uzoaganobi. Formulation of Domperidone Microspheres Using a Combination of Locally Extracted Chitosan and Hpmc as Polymers. J Chem Chem Eng. 2017;11(2):65–74.
13. Patel D, Sawant K. Self Micro-Emulsifying Drug Delivery System: Formulation Development and Biopharmaceutical Evaluation of Lipophilic Drugs. Curr Drug Deliv. 2009;6(4):419–24.
14. Prajapati BG, Patel D V. Formulation and optimization of domperidone fast dissolving tablet by wet granulation techniques using factorial design. Int J PharmTech Res. 2010;2(1):292–9.
15. Khan Sadozai S, Ahmad Chishti K, Ullah R, Hussain Z, Khan Sadozai M, Ur Rahman S, et al. Formulation development and evaluation of domperidone sustained release matrix tablets by two different methods using guar gum as a sustaining agent. World Appl Sci J. 2013;25(12):1704–12.
16. Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl. 1984;19(96):127–36.
17. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986 Sep 1;135(5):457–61.
18. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981 Jan;6(1):49–60.
19. Barone JA. Domperidone: A Peripherally Acting Dopamine 2 -Receptor Antagonist. Ann Pharmacother. 1999 Apr 28;33(4):429–40.
20. Naonori K, Hiroshi Y, Ken I, Katsumi M. A new type of a pH-independent controlled release tablet. Int J Pharm. 1991 Feb;68(1–3):255–64.
21. Thoma K, Zimmer T. Retardation of weakly basic drugs with diffusion tablets. Int J Pharm. 1990;58(3):197–202.
22. McCallum RW. Review of the Current Status of Prokinetic Agents in Gastroenterology. Am J Gastroenterol. 1985;80(12):1008–16.
23. Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol. 1983;89(1):137–41.
24. Reynolds JC, Putnam PE. Prokinetic agents. [Internet]. Vol. 21, Gastroenterology clinics of North America. 1992. 530–536 p. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1516959.
25. Washabau RJ. Prokinetic Agents. In: Canine and Feline Gastroenterology. 2012. p. 530–6. 26. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, et al. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994;268(1):417–26.
27. Barone JA. Domperidone: A peripherally acting dopamine2-receptor antagonist. Vol. 33, Annals of Pharmacotherapy. 1999. p. 429–40.
28. Corinaldesi R, Stanghellini V, Zarabini GE. The effect of domperidone on the gastric emptying of solid and liquid phases of a mixed meal in patients with dyspepsia. Curr Ther Res – Clin Exp. 1983;34(4):982–6.
29. Del Genio A, Di Martino N, Piccolo S, Maffettone V, Landolfi V, Salvatore M. The effect of domperidone on gastric emptying in reflux esophagitis: A radioisotopic study. J Nucl Med Allied Sci. 1984;28(4):251–6.
30. Baeyens R, van De Velde E, de Schepper A, Wollaert F, Reyntjens A. Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J. 1979;55:19–23.
31. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–75.
32. Maddern G, Horowitz M, Jamieson G. The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy. Br J Clin Pharmacol. 1985 Apr;19(4):441–4.
33. Weihrauch TR, Foerster Ch. F, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J. 1979; 34. Brock-Utne JG, Downing JW, Dimopoulos GE, Rubin J, Moshal MG. Effect of Domperidone on Lower Esophageal Sphincter Tone in Late Pregnancy. Anesthesiology. 1980 Apr 1;52(4):321–3.
35. Sowers JR, Sharp B, McCallum RW. Effect of Domperidone, an Extracerebral Inhibitor of Dopamine Receptors, on Thyrotropin, Prolactin, Renin, Aldosterone, and 18- Hydroxycorticosterone Secretion in Man. J Clin Endocrinol Metab. 1982;54(4):869–71.
36. Brouwers JRBJ, Assies J, Wiersinga WM, Huizing G, Tytgat GN. Plasma Prolactin Levels after Acute and Subchronic Oral Administration of Domperidone and Metoclopramide: A Cross-Over Study in Healthy Volunteers. Clin Endocrinol (Oxf). 1980 May;12(5):435–40.
37. Niemegeers CJE, Schellekens KHL, Janssen PAJ. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther. 1980;244(1):130–40.
38. Degli Uberti EC, Trasforini GC, Margutti AR, Sammaroli SR, Fersini C, Pansini R. Plasma aldosterone response to domperidone, an extracerebral dopamine receptor blocker, in normal subjects. Panminerva Med. 1981;23(3):183–6.
39. Huang Y ‐C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP. Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers. J Clin Pharmacol. 1986;26(8):628–32.
40. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
41. Michiels M, Hendriks R, Heykants J. On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet. 1981;6(1):37–48.
42. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
43. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981;6(1):49–60.
44. Simard C, Michaude V, Gibbs B, Massé R, Lessardu É, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34(11–12):1013– 23.
45. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4- tetrahydro- 6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, a. J Pharmacol Exp Ther. 2004;310(2):703–9.
46. Youssef AS, Parkman HP, Nagar S. Drug-drug interactions in pharmacologic management of gastroparesis. Neurogastroenterol Motil. 2015 Nov;27(11):1528–41.
47. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica. 2009 Oct 3;39(10):749–56.
48. Lim HK, Duczak N, Brougham L, Elliot M, Patel K, Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos. 2005;33(8):1211–9.
49. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014;44(9):792–803.
50. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: A randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.
51. Alhumayyd MS, Bukhari IA, Almotrefi AA. Effect of piperine, amajor component of black pepper, on the pharmacokinetics of domperidone in rats. J Physiol Pharmacol. 2014;65(6):785–9.
52. Harris RZ, Jang GR, Tsunoda S. Dietary Effects on Drug Metabolism and Transport. Vol. 42, Clinical Pharmacokinetics. 2003. p. 1071–88.
53. Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. Impact of the changes in P- glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Reports. 2007;59(6):752–6.
54. Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(4):182–4.
55. Shindler J, Finnerty G, Towlson K, Dolan A, Davies C, Parkes J. Domperidone and levodopa in Parkinson’s disease. Br J Clin Pharmacol. 1984;18(6):959–62.
56. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: An in vitro analysis. Xenobiotica. 2009;39(10):749–56.
57. Jain P, Goel A, Sharma S, Parmar M. Solubility Enhancement Techniques with Special Emphasis on Hydrotrophy. Int J Pharma Prof Res. 2010;1(1):34–45.
58. Patil HG, Tiwari R V., Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42(6):906–15.
59. Sutradhar KB, Akhter DT, Uddin R. Formulation and evaluation of taste masked oral dispersible tablets of Domperidone using sublimation method. Int J Pharm Pharm Sci. 2012;4(2):727–32.
60. Aboutaleb AE, Abdel-Rahman SI, Ahmed MO, Younis MA. Improvement of domperidone solubility and dissolution rate by dispersion in various hydrophilic carriers. J Appl Pharm Sci. 2016;6(7):133–9.
61. Nagpal M, Kaur L, Chander J, Sharma P. Dissolution Enhancement of Domperidone Fast Disintegrating Tablet Using Modified Locust Bean Gum by Solid Dispersion Technique. J Pharm Technol Res Manag. 2016;4(1):1–11.
62. Patel D, Patel S, Patel C. Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion. Int J Pharm Investig. 2014;4(4):174–82.
63. Palem CR, Kumar Battu S, Maddineni S, Gannu R, Repka MA, Yamsani MR. Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. Pharm Dev Technol. 2013 Feb 13;18(1):186–95.
64. Thapa P, Thapa R, Budhathoki U, Thapa P. Solubility Enhancement of Domperidone Fast Disintegrating Tablet Using Hydroxypropyl-β-Cyclodextrin by Inclusion Complexation Technique. Pharmacol & Pharm. 2014;5(3):238–49.
65. Khan W, Siddique NF, Siddiqui J, Hussain Z, Farooqui S. Formulation and Evaluation of Domperidone Sustained Release Tablet. Res J Pharm Technol. 2018;11(12):5599–610.
66. Enteshari S, Varshosaz J. Solubility Enhancement of Domperidone by Solvent Change In situ Micronization Technique. Adv Biomed Res. 2018;7(1):1–8.
67. Zayed GM, Rasoul SA El, Ibrahim MA, Saddik MS, Alshora DH. In vitro and in vivo characterization of domperidone-loaded fast dissolving buccal films. Saudi Pharm J. 2020;28(3):266–73.
68. Kibria G, Akhter A, Ariful Islam K. Formulation and evaluation of domperidone pellets prepared by powder layering technology. Asian J Pharm. 2010;4(1):41–7.
69. Ramu A, Vidyadhara S, Devanna N, Naidu U, Kalyani P. Formulation and evaluation of irbesartan fast dissolving tablets. Asian J Pharm. 2013;7(2):61–7.

nn[/if 1104] [if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””], [/if 1106]
  2. n[/foreach]

n[/if 1104]

n[if 1114 equals=”Yes”]n

n[/if 1114]

n

n

[if 424 not_equal=”Regular Issue”] Regular Issue[/if 424] Open Access Article

n

Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

n

“},{“box”:4,”content”:”

n“},{“box”:1,”content”:”

    By  [foreach 286]n

  1. n

    M.A.K. Azad, Md. Masudur Rahman, Shimul Halder, Eva Rahman Kabir

    n

  2. [/foreach]

n

    [foreach 286] [if 1175 not_equal=””]n t

  1. Assistant Professor, Research Scholar, Associate Professor, Professor,Department of Pharmacy, BRAC University, Mohakhali, Department of Pharmacy, BRAC University, Mohakhali, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Department of Pharmacy, BRAC University, Mohakhali,Dhaka, Dhaka, Dhaka, Dhaka,Bangladesh, Bangladesh, Bangladesh, Bangladesh
  2. n[/if 1175][/foreach]

n

n

n

n

n

Abstract

nDomperidone (DMP), a potent gastroprokinetic and antiemetic drug, exhibits poor aqueous solubility and limited oral bioavailability. Therefore, to develop oral preparations with optimized oral bioavailability, the pharmacokinetic parameters of DMP need to be controlled. The present review aimed to discuss the physicochemical characteristics of DMP causing its unfavorable oral delivery, to explore the viable oral formulation approaches, and to propose some recent formulation approaches that can mitigate the above mentioned difficulties in delivering DMP. In this study, some effective strategies in terms of pharmacokinetic behavior of DMP have been comparatively discussed. It has been recommended that, the amorphous solid dispersion approach could be more convincing from the scalability perspective along with its significant improvement in dissolution behavior and oral bioavailability. Finally, some future perspectives of these strategies have also been addressed to facilitate efficient formulation development.n

n

n

Keywords: Domperidone; solubility; drug delivery strategy; pharmacokinetic, bioavailability.

n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)]

n[/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue under section in Trends in Drug Delivery(tdd)] [/if 424]

n

n

n


n[if 992 equals=”Subscription”]n

n

n

Full Text

n

n

nn[/if 992]n[if 992 not_equal=”Subscription”]n

n

Full Text

n

n

n

n


[/if 992]n[if 379 not_equal=””]

Browse Figures

n

n

[foreach 379]n

n[/foreach]

n

[/if 379]n

n

References

n[if 1104 equals=””]

1. Vetrivel N, Praveen D, Ranadheer Chowdary P, Elan Cheziyan K, Vijey Aanandhi M. Comparison of safety and effectiveness of ondansetron and domperidone in patients with gastrointestinal problems. Drug Invent Today. 2018;10(3):343–6.
2. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6(6):571–6.
3. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005;81(1):211–9.
4. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: A Review of its Pharmacological Activity, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic. Drugs. 1982;24(5):360–400.
5. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: Review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm Res An Off J Am Assoc Pharm Sci. 1995;12(3):413–20.
7. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144–56.
8. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm. 2011;420(1):1–10.
9. Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P, et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137.
10. Patel K, Prasad RK, Bajpai M. Enhancement of dissolution rate of domperidone using melt granulation technique. Der Pharm Lett. 2011;3(2):25–33.
11. Tyagi R, Dhillon V. Enhancement of Solubility and Dissolution Rate of Domperidone Using Cogrinding and Kneading Technique. J Drug Deliv Ther. 2012 Jul 15;2(4):152–4.
12. Stephen Olaribigbe Majekodunmi, Cynthia Chibuzor Uzoaganobi. Formulation of Domperidone Microspheres Using a Combination of Locally Extracted Chitosan and Hpmc as Polymers. J Chem Chem Eng. 2017;11(2):65–74.
13. Patel D, Sawant K. Self Micro-Emulsifying Drug Delivery System: Formulation Development and Biopharmaceutical Evaluation of Lipophilic Drugs. Curr Drug Deliv. 2009;6(4):419–24.
14. Prajapati BG, Patel D V. Formulation and optimization of domperidone fast dissolving tablet by wet granulation techniques using factorial design. Int J PharmTech Res. 2010;2(1):292–9.
15. Khan Sadozai S, Ahmad Chishti K, Ullah R, Hussain Z, Khan Sadozai M, Ur Rahman S, et al. Formulation development and evaluation of domperidone sustained release matrix tablets by two different methods using guar gum as a sustaining agent. World Appl Sci J. 2013;25(12):1704–12.
16. Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl. 1984;19(96):127–36.
17. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986 Sep 1;135(5):457–61.
18. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981 Jan;6(1):49–60.
19. Barone JA. Domperidone: A Peripherally Acting Dopamine 2 -Receptor Antagonist. Ann Pharmacother. 1999 Apr 28;33(4):429–40.
20. Naonori K, Hiroshi Y, Ken I, Katsumi M. A new type of a pH-independent controlled release tablet. Int J Pharm. 1991 Feb;68(1–3):255–64.
21. Thoma K, Zimmer T. Retardation of weakly basic drugs with diffusion tablets. Int J Pharm. 1990;58(3):197–202.
22. McCallum RW. Review of the Current Status of Prokinetic Agents in Gastroenterology. Am J Gastroenterol. 1985;80(12):1008–16.
23. Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol. 1983;89(1):137–41.
24. Reynolds JC, Putnam PE. Prokinetic agents. [Internet]. Vol. 21, Gastroenterology clinics of North America. 1992. 530–536 p. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1516959.
25. Washabau RJ. Prokinetic Agents. In: Canine and Feline Gastroenterology. 2012. p. 530–6. 26. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, et al. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994;268(1):417–26.
27. Barone JA. Domperidone: A peripherally acting dopamine2-receptor antagonist. Vol. 33, Annals of Pharmacotherapy. 1999. p. 429–40.
28. Corinaldesi R, Stanghellini V, Zarabini GE. The effect of domperidone on the gastric emptying of solid and liquid phases of a mixed meal in patients with dyspepsia. Curr Ther Res – Clin Exp. 1983;34(4):982–6.
29. Del Genio A, Di Martino N, Piccolo S, Maffettone V, Landolfi V, Salvatore M. The effect of domperidone on gastric emptying in reflux esophagitis: A radioisotopic study. J Nucl Med Allied Sci. 1984;28(4):251–6.
30. Baeyens R, van De Velde E, de Schepper A, Wollaert F, Reyntjens A. Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J. 1979;55:19–23.
31. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–75.
32. Maddern G, Horowitz M, Jamieson G. The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy. Br J Clin Pharmacol. 1985 Apr;19(4):441–4.
33. Weihrauch TR, Foerster Ch. F, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J. 1979; 34. Brock-Utne JG, Downing JW, Dimopoulos GE, Rubin J, Moshal MG. Effect of Domperidone on Lower Esophageal Sphincter Tone in Late Pregnancy. Anesthesiology. 1980 Apr 1;52(4):321–3.
35. Sowers JR, Sharp B, McCallum RW. Effect of Domperidone, an Extracerebral Inhibitor of Dopamine Receptors, on Thyrotropin, Prolactin, Renin, Aldosterone, and 18- Hydroxycorticosterone Secretion in Man. J Clin Endocrinol Metab. 1982;54(4):869–71.
36. Brouwers JRBJ, Assies J, Wiersinga WM, Huizing G, Tytgat GN. Plasma Prolactin Levels after Acute and Subchronic Oral Administration of Domperidone and Metoclopramide: A Cross-Over Study in Healthy Volunteers. Clin Endocrinol (Oxf). 1980 May;12(5):435–40.
37. Niemegeers CJE, Schellekens KHL, Janssen PAJ. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther. 1980;244(1):130–40.
38. Degli Uberti EC, Trasforini GC, Margutti AR, Sammaroli SR, Fersini C, Pansini R. Plasma aldosterone response to domperidone, an extracerebral dopamine receptor blocker, in normal subjects. Panminerva Med. 1981;23(3):183–6.
39. Huang Y ‐C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP. Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers. J Clin Pharmacol. 1986;26(8):628–32.
40. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
41. Michiels M, Hendriks R, Heykants J. On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet. 1981;6(1):37–48.
42. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70.
43. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981;6(1):49–60.
44. Simard C, Michaude V, Gibbs B, Massé R, Lessardu É, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34(11–12):1013– 23.
45. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4- tetrahydro- 6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, a. J Pharmacol Exp Ther. 2004;310(2):703–9.
46. Youssef AS, Parkman HP, Nagar S. Drug-drug interactions in pharmacologic management of gastroparesis. Neurogastroenterol Motil. 2015 Nov;27(11):1528–41.
47. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica. 2009 Oct 3;39(10):749–56.
48. Lim HK, Duczak N, Brougham L, Elliot M, Patel K, Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos. 2005;33(8):1211–9.
49. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014;44(9):792–803.
50. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: A randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.
51. Alhumayyd MS, Bukhari IA, Almotrefi AA. Effect of piperine, amajor component of black pepper, on the pharmacokinetics of domperidone in rats. J Physiol Pharmacol. 2014;65(6):785–9.
52. Harris RZ, Jang GR, Tsunoda S. Dietary Effects on Drug Metabolism and Transport. Vol. 42, Clinical Pharmacokinetics. 2003. p. 1071–88.
53. Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. Impact of the changes in P- glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Reports. 2007;59(6):752–6.
54. Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(4):182–4.
55. Shindler J, Finnerty G, Towlson K, Dolan A, Davies C, Parkes J. Domperidone and levodopa in Parkinson’s disease. Br J Clin Pharmacol. 1984;18(6):959–62.
56. Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: An in vitro analysis. Xenobiotica. 2009;39(10):749–56.
57. Jain P, Goel A, Sharma S, Parmar M. Solubility Enhancement Techniques with Special Emphasis on Hydrotrophy. Int J Pharma Prof Res. 2010;1(1):34–45.
58. Patil HG, Tiwari R V., Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42(6):906–15.
59. Sutradhar KB, Akhter DT, Uddin R. Formulation and evaluation of taste masked oral dispersible tablets of Domperidone using sublimation method. Int J Pharm Pharm Sci. 2012;4(2):727–32.
60. Aboutaleb AE, Abdel-Rahman SI, Ahmed MO, Younis MA. Improvement of domperidone solubility and dissolution rate by dispersion in various hydrophilic carriers. J Appl Pharm Sci. 2016;6(7):133–9.
61. Nagpal M, Kaur L, Chander J, Sharma P. Dissolution Enhancement of Domperidone Fast Disintegrating Tablet Using Modified Locust Bean Gum by Solid Dispersion Technique. J Pharm Technol Res Manag. 2016;4(1):1–11.
62. Patel D, Patel S, Patel C. Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion. Int J Pharm Investig. 2014;4(4):174–82.
63. Palem CR, Kumar Battu S, Maddineni S, Gannu R, Repka MA, Yamsani MR. Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. Pharm Dev Technol. 2013 Feb 13;18(1):186–95.
64. Thapa P, Thapa R, Budhathoki U, Thapa P. Solubility Enhancement of Domperidone Fast Disintegrating Tablet Using Hydroxypropyl-β-Cyclodextrin by Inclusion Complexation Technique. Pharmacol & Pharm. 2014;5(3):238–49.
65. Khan W, Siddique NF, Siddiqui J, Hussain Z, Farooqui S. Formulation and Evaluation of Domperidone Sustained Release Tablet. Res J Pharm Technol. 2018;11(12):5599–610.
66. Enteshari S, Varshosaz J. Solubility Enhancement of Domperidone by Solvent Change In situ Micronization Technique. Adv Biomed Res. 2018;7(1):1–8.
67. Zayed GM, Rasoul SA El, Ibrahim MA, Saddik MS, Alshora DH. In vitro and in vivo characterization of domperidone-loaded fast dissolving buccal films. Saudi Pharm J. 2020;28(3):266–73.
68. Kibria G, Akhter A, Ariful Islam K. Formulation and evaluation of domperidone pellets prepared by powder layering technology. Asian J Pharm. 2010;4(1):41–7.
69. Ramu A, Vidyadhara S, Devanna N, Naidu U, Kalyani P. Formulation and evaluation of irbesartan fast dissolving tablets. Asian J Pharm. 2013;7(2):61–7.

n[/if 1104][if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
  2. n[/foreach]

n[/if 1104]

n


n[if 1114 equals=”Yes”]n

n[/if 1114]”},{“box”:2,”content”:”

Regular Issue Open Access Article

n

n

n

n

n

Trends in Drug Delivery

n

[if 344 not_equal=””]ISSN: 2394-7268[/if 344]

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

Volume 8
Issue 2
Received May 27, 2021
Accepted August 10, 2021
Published August 25, 2021

n

n

n

n

Editor

n

n


n

Reviewer

n

n


n n

n”},{“box”:6,”content”:”“}]

Read More
TDD

An Insight to Diagnosis and Management of Druginduced Hepatotoxicity: An Overview

[{“box”:0,”content”:”

n

n

 > 

n

n

 > 

n

n

n

n

n

n

n

By [foreach 286]u00a0

u00a0Asad Jamal Ansari,

[/foreach]
nJanuary 10, 2023 at 7:07 am

n

nAbstract

n

(ADRs) Adverse Drug Reactions are constitute and mutual chief health problem. Throughout the last period liver toxicity has remained one of the most recurrent reasons for pharmacovigilance protection intelligences and the withdrawal from the marketplace of an accepted medicinal product. Liver is a main organ elaborate in the systemic deposition and decontamination of exogenous and endogenous ingredients. Liver disfunction challenges not only health care specialists but also the pharmaceutical manufacturing and drug controlling agencies. (DILI) Drug Induced Liver Injury also mentioned as drug induced hepatotoxicity, formulae a main clinical problematic, which has developed the foremost cause of transplantation and acute liver failure in Western countries. Drug induced hepatotoxicity is one of the chief reasons of chronic and acute liver disease. The Liver, a supreme organ is the Principal site for metabolism of nutrients and energy manufacture in the human body. It is also essential for elimination and metabolism of exogenous drugs and injurious materials via kidney. Hepatotoxicity produced by a diversity of environmental contaminants, viruses, pathogenic micro-organism chemical and drugs agents may account for Several types of drug induced liver diseases are acute-dose reliant acute fatty infiltration, liver damage, cholestatic jaundice, active chronic hepatitis, liver granulomas, liver tumors, liver cirrhosis, liver tumors etc. Furthermore, there is no precise management for hepatotoxicity, which is grounded on appending the assumed drug and treating symptoms. The most normally connected pharmacological groups are nonsteroidal anti-inflammatory analgesics (NSAIDs), antibiotics, anticonvulsants and antidepressants. Drug induced liver injury has remained an adverse occasion, tough to recognize, treat and prevent; thus, the pharmacist interference can subsidize to the decrease of the harmful belongings in patient health. So, in this review we highlighted the pathogenesis, diagnosis and management of drug induced hepatoxicity.

n

n

n

n

Volume :u00a0u00a08 | Issue :u00a0u00a02 | Received :u00a0u00a0July 6, 2021 | Accepted :u00a0u00a0August 10, 2021 | Published :u00a0u00a0August 25, 2021n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)] [/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue An Insight to Diagnosis and Management of Druginduced Hepatotoxicity: An Overview under section in Trends in Drug Delivery(tdd)] [/if 424]
Keywords Drug-Induced Hepatotoxicity, Diagnosis, Mechanisms of hepatotoxicity and Hepatoprotectives agents

n

n

n

n

n


n[if 992 equals=”Transformative”]

n

n

Full Text

n

n

n

[/if 992][if 992 not_equal=”Transformative”]

n

n

Full Text

n

n

n

[/if 992] n


nn

[if 379 not_equal=””]n

[foreach 379]n

n[/foreach]

n[/if 379]

n

References

n[if 1104 equals=””]n

1. Su LJ, Ding GW, Yang ZL, Zhang SB, Yang YX, Xu CS. Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration. World Journal of Gastroenterology: WJG. 2006 Dec 21;12(47):7626.
2. Lu Y, Hu D, Ma S, Zhao X, Wang S, Wei G, Wang X, Wen A, Wang J. Protective effect of wedelolactone against CCl4-induced acute liver injury in mice. International immunopharmacology. 2016 May 1;34:44-52.
3. Woolbright BL, Jaeschke H. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. Current pharmacology reports. 2018 Oct;4(5):346-57.
4. Masuda Y. Learning toxicology from carbon tetrachloride-induced hepatotoxicity. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan. 2006 Oct 1;126(10):885-99.
5. Singh D, Cho WC, Upadhyay G. Drug-induced liver toxicity and prevention by herbal antioxidants: an overview. Frontiers in physiology. 2016 Jan 26;6:363.
6. Lee WM. Drug-induced hepatotoxicity. New England journal of medicine. 2003 Jul 31;349(5):474- 85.
7. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of internal medicine. 2002 Dec 17;137(12):947-54.
8. Hernández N, Bessone F, Sánchez A, Di Pace M, Brahm J, Zapata R, Chirino RA, Dávalos M, Méndez-Sánchez N, Arrese M, Schinoni M. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of hepatology. 2014 Apr 21;13(2):231-9.
9. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA. Hepatic histological findings in suspected drug‐ induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb;59(2):661-70.

nn[/if 1104] [if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””], [/if 1106]
  2. n[/foreach]

n[/if 1104]

n[if 1114 equals=”Yes”]n

n[/if 1114]

n

n

[if 424 not_equal=”Regular Issue”] Regular Issue[/if 424] Open Access Article

n

Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

n

“},{“box”:4,”content”:”

n“},{“box”:1,”content”:”

    By  [foreach 286]n

  1. n

    Asad Jamal Ansari

    n

  2. [/foreach]

n

    [foreach 286] [if 1175 not_equal=””]n t

  1. ,,,
  2. n[/if 1175][/foreach]

n

n

n

n

n

Abstract

n(ADRs) Adverse Drug Reactions are constitute and mutual chief health problem. Throughout the last period liver toxicity has remained one of the most recurrent reasons for pharmacovigilance protection intelligences and the withdrawal from the marketplace of an accepted medicinal product. Liver is a main organ elaborate in the systemic deposition and decontamination of exogenous and endogenous ingredients. Liver disfunction challenges not only health care specialists but also the pharmaceutical manufacturing and drug controlling agencies. (DILI) Drug Induced Liver Injury also mentioned as drug induced hepatotoxicity, formulae a main clinical problematic, which has developed the foremost cause of transplantation and acute liver failure in Western countries. Drug induced hepatotoxicity is one of the chief reasons of chronic and acute liver disease. The Liver, a supreme organ is the Principal site for metabolism of nutrients and energy manufacture in the human body. It is also essential for elimination and metabolism of exogenous drugs and injurious materials via kidney. Hepatotoxicity produced by a diversity of environmental contaminants, viruses, pathogenic micro-organism chemical and drugs agents may account for Several types of drug induced liver diseases are acute-dose reliant acute fatty infiltration, liver damage, cholestatic jaundice, active chronic hepatitis, liver granulomas, liver tumors, liver cirrhosis, liver tumors etc. Furthermore, there is no precise management for hepatotoxicity, which is grounded on appending the assumed drug and treating symptoms. The most normally connected pharmacological groups are nonsteroidal anti-inflammatory analgesics (NSAIDs), antibiotics, anticonvulsants and antidepressants. Drug induced liver injury has remained an adverse occasion, tough to recognize, treat and prevent; thus, the pharmacist interference can subsidize to the decrease of the harmful belongings in patient health. So, in this review we highlighted the pathogenesis, diagnosis and management of drug induced hepatoxicity.n

n

n

Keywords: Drug-Induced Hepatotoxicity, Diagnosis, Mechanisms of hepatotoxicity and Hepatoprotectives agents

n[if 424 equals=”Regular Issue”][This article belongs to Trends in Drug Delivery(tdd)]

n[/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue under section in Trends in Drug Delivery(tdd)] [/if 424]

n

n

n


n[if 992 equals=”Subscription”]n

n

n

Full Text

n

n

nn[/if 992]n[if 992 not_equal=”Subscription”]n

n

Full Text

n

n

n

n


[/if 992]n[if 379 not_equal=””]

Browse Figures

n

n

[foreach 379]n

n[/foreach]

n

[/if 379]n

n

References

n[if 1104 equals=””]

1. Su LJ, Ding GW, Yang ZL, Zhang SB, Yang YX, Xu CS. Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration. World Journal of Gastroenterology: WJG. 2006 Dec 21;12(47):7626.
2. Lu Y, Hu D, Ma S, Zhao X, Wang S, Wei G, Wang X, Wen A, Wang J. Protective effect of wedelolactone against CCl4-induced acute liver injury in mice. International immunopharmacology. 2016 May 1;34:44-52.
3. Woolbright BL, Jaeschke H. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. Current pharmacology reports. 2018 Oct;4(5):346-57.
4. Masuda Y. Learning toxicology from carbon tetrachloride-induced hepatotoxicity. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan. 2006 Oct 1;126(10):885-99.
5. Singh D, Cho WC, Upadhyay G. Drug-induced liver toxicity and prevention by herbal antioxidants: an overview. Frontiers in physiology. 2016 Jan 26;6:363.
6. Lee WM. Drug-induced hepatotoxicity. New England journal of medicine. 2003 Jul 31;349(5):474- 85.
7. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of internal medicine. 2002 Dec 17;137(12):947-54.
8. Hernández N, Bessone F, Sánchez A, Di Pace M, Brahm J, Zapata R, Chirino RA, Dávalos M, Méndez-Sánchez N, Arrese M, Schinoni M. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of hepatology. 2014 Apr 21;13(2):231-9.
9. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA. Hepatic histological findings in suspected drug‐ induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb;59(2):661-70.

n[/if 1104][if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
  2. n[/foreach]

n[/if 1104]

n


n[if 1114 equals=”Yes”]n

n[/if 1114]”},{“box”:2,”content”:”

Regular Issue Open Access Article

n

n

n

n

n

Trends in Drug Delivery

n

[if 344 not_equal=””]ISSN: 2394-7268[/if 344]

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

Volume 8
Issue 2
Received July 6, 2021
Accepted August 10, 2021
Published August 25, 2021

n

n

n

n

Editor

n

n


n

Reviewer

n

n


n n

n”},{“box”:6,”content”:”“}]

Read More
TDD

Anti-Inflammatory drug delivery of Neurodegenerative disease

[{“box”:0,”content”:”

n

n

Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

n

n

n

n

n

n

Open Access

n

Special Issue

n

Topic

n

n Anti-Inflammatory drug delivery of Neurodegenerative diseasen

n

Abstract Submission Deadline : November 30, 2023

n

Manuscript Submission Deadline : December 25, 2023

n [if 457 equals=”Special Issue”]

[This article belongs to Special Issue Anti-Inflammatory drug delivery of Neurodegenerative disease under section tdd in Trends in Drug Delivery(tdd)] [/if 457]n

n Special Issue Descriptionn

The immune system’s biological response to an irritant is inflammation, which serves to defend living things from harm. However, excessive and unchecked inflammation is linked to several deadly Neurodegenerative disorders, such as Alzheimer’s, Dementia, Huntington’s disease, etc. A wide range of anti-inflammatory therapies are now available for the treatment and management of pertinent chronic diseases thanks to advances in our understanding of the inflammatory response. Despite these achievements, patients’ clinical outcomes vary, and major side effects are frequently reported. Additionally, there are some restrictions for clinical anti-inflammatory therapies, including inadequate access to subcellular compartments, low bioavailability, off-target effects, and water insolubility. The rational design of inflammation-specific drug delivery systems (DDSs) offers tremendous potential for overcoming these difficulties. Additionally, compared to normal tissues, the pathological milieu associated with inflamed tissues (such as oxidative stress, an acidic pH, and overexpressed enzymes) offers crucial biochemical triggers for the triggered administration of anti-inflammatory drugs in a spatiotemporally regulated way. For the treatment of neuroinflammatory illnesses, we highlight current developments in the creation of anti-inflammatory DDSs with an integrated pathological inflammation-specific response.

n [if 233 not_equal=””]Editor [foreach 234]n

,

n [/foreach][/if 233]n Keywordsn

Anti-Inflammatory agents, Drug delivery system, Inflammation, Stimuli-responsive polymers

n Manuscript Submission informationn

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.n All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.n Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

n Participating journals:n

n

[foreach 176] n  2394-7268n [/foreach]

n

n

Journal Name

nTrends in Drug Deliveryn

n

n

Abbrivation

n tddn

n

n

ISSN

n

n 2394-7268

n

n

Since

n

2014

n

n

APC

950u00a0 $

n

n

n

n[if 259 not_equal=””]

Published articles

View Published Paper[/if 259]n

n

n

n

n

n